LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

LLY

1,006.74

-1.12%↓

JNJ

229.99

-0.1%↓

ABBV

210.58

+1.02%↑

UNH

400.55

-0.16%↓

AZN

185.18

-0.81%↓

Home・Akciju saraksts・Certara Inc

Certara Inc

Atvērts

SektorsVeselības aprūpe

4.71 -2.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.68

Max

4.91

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.9M -8.8M
Pārdošana	3.3M 107M
P/E Sektora vidējais	100.714 51.415
EPS	0.09
Peļņas marža	-8.196
Darbinieki	1,515
EBITDA	-30M 1.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+56.78% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-236M 798M
Iepriekšējā atvēršanas cena	7.19
Iepriekšējā slēgšanas cena	4.71

Ziņu noskaņojums

By Acuity

20%

80%

45 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

11.27 / 12.79 Atbalsts un pretestība

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. maijs 22:54 UTC

Peļņas

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 13. maijs 23:17 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 13. maijs 23:16 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026. g. 13. maijs 23:15 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026. g. 13. maijs 23:14 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026. g. 13. maijs 23:02 UTC

Tirgus saruna

Peļņas

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026. g. 13. maijs 22:59 UTC

Tirgus saruna

Peļņas

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026. g. 13. maijs 22:24 UTC

Peļņas

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Revenue Growth 47%>XRO.AU

2026. g. 13. maijs 22:22 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026. g. 13. maijs 22:18 UTC

Peļņas

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026. g. 13. maijs 22:16 UTC

Peļņas

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026. g. 13. maijs 22:13 UTC

Peļņas

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026. g. 13. maijs 22:12 UTC

Peļņas

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero Did Not Declare a Dividend>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026. g. 13. maijs 22:09 UTC

Peļņas

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026. g. 13. maijs 22:00 UTC

Peļņas

Cisco to Shed Jobs for All-In AI Push -- Update

2026. g. 13. maijs 21:11 UTC

Peļņas

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

56.78% augšup

Prognoze 12 mēnešiem

Vidējais 7.51 USD 56.78%

Augstākais 10 USD

Zemākais 5.13 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Certara Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

45 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.